Health
Monoclonal antibodies can help high-risk people with COVID-19. But getting the drug to patients remains challe – The Philadelphia Inquirer
Demand for the drugs, which are the only approved treatment for high-risk patients who don’t need to be in the hospital, is lower than expected.
Back in December, the big worry about two newly approved treatments for early COVID-19 was that demand would far outstrip supply.
After all, some famous men had taken monoclonal antibodies after they were infected in the fall some of them before the drugs received emergency-use authorization and became highly visible converts.
Former President Donald Trump called a drug made by Regeneron a cure. (He was also given other treatments that may have helped him recover.) Ben Carson, former secretary of…
-
Business15 hours ago1 ASX dividend stock down 43% I’d buy right now
-
Noosa News15 hours agoBanana farmers still salvaging fruit four weeks after ex-Tropical Cyclone Alfred
-
Noosa News14 hours agoQueen Street Mall to get a 3D digital billboard; Dutton dumps controversial plans to end flexible work; Measles alert for tourist hotspots
-
Business19 hours agoBattle of the ASX ETFs: Why has VGS outperformed VTS this year?